Establishing a Primary Lung Cancer Model to Identify Mutant Subpopulations That Cause Resistance to Molecularly-targeted Cancer Therapies.

被引：0
|
作者：
Banda, M. [1 ]
McKim, K. L. [2 ]
Myers, M. B. [2 ]
Parsons, B. L. [2 ]
机构：
[1] Covance Labs Inc, Indianapolis, IN USA
[2] US FDA, NCTR, Div Genet & Mol Toxicol, Jefferson, AR USA
来源：
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS | 2018年 / 59卷
关键词：
D O I：
暂无
中图分类号：
X [环境科学、安全科学];
学科分类号：
08 ; 0830 ;
摘要：
S46
引用
收藏
页码：49 / 49
页数：1
相关论文
共 50 条
  • [21] Molecularly targeted therapies for oncogene-driven advanced non-small-cell lung cancer
    Okamoto, Isamu
    CANCER SCIENCE, 2018, 109 : 1224 - 1224
  • [22] TARGETED THERAPIES Afatinib-new therapy option for EGFR-mutant lung cancer
    Yu, Helena A.
    Pao, William
    NATURE REVIEWS CLINICAL ONCOLOGY, 2013, 10 (10) : 551 - 552
  • [23] Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer
    Delahaye, Celia
    Figarol, Sarah
    Pradines, Anne
    Favre, Gilles
    Mazieres, Julien
    Calvayrac, Olivier
    CANCERS, 2022, 14 (11)
  • [24] Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer
    Della Corte, Carminia Maria
    Fasano, Morena
    Papaccio, Federica
    Ciardiello, Fortunato
    Morgillo, Floriana
    BIOMEDICINES, 2014, 2 (04): : 345 - 358
  • [25] Molecularly targeted therapies in non-small cell lung cancer: The evolving role of tyrosine kinase inhibitors
    Doval, D.
    Desai, C.
    Sahoo, T.
    INDIAN JOURNAL OF CANCER, 2019, 56 (05) : 23 - 30
  • [26] Neuroendocrine Transformation as a Mechanism of Resistance to Targeted Lung Cancer Therapies: Emerging Mechanisms and Their Therapeutic Implications
    Joshi, Asim
    Bhaskar, Nivitha
    Pearson, Joel D.
    CANCERS, 2025, 17 (02)
  • [27] Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer
    Annie Roys
    Xing Chang
    Yang Liu
    Xiaobo Xu
    Yingliang Wu
    Daiying Zuo
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 679 - 688
  • [28] Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
    Arjan Gower
    Yisong Wang
    Giuseppe Giaccone
    Journal of Molecular Medicine, 2014, 92 : 697 - 707
  • [29] Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer
    Roys, Annie
    Chang, Xing
    Liu, Yang
    Xu, Xiaobo
    Wu, Yingliang
    Zuo, Daiying
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 679 - 688
  • [30] Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
    Gower, Arjan
    Wang, Yisong
    Giaccone, Giuseppe
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2014, 92 (07): : 697 - 707
12345